| Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. | |
| | |
MedLine Citation:
|
PMID: 22241177 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a variety of cells in situ, including antigen-presenting cells (APCs). Engineering LVs to specifically transduce APCs is required to promote their translation towards the clinic. We report on the Nanobody (Nb) display technology to target LVs to dendritic cells (DCs) and macrophages. This innovative approach exploits the budding mechanism of LVs to incorporate an APC-specific Nb and a binding-defective, fusion-competent form of VSV.G in the viral envelope. In addition to production of high titer LVs, we demonstrated selective, Nb-dependent transduction of mouse DCs and macrophages both in vitro and in situ. Moreover, this strategy was translated to a human model in which selective transduction of in vitro generated or lymph node (LN)-derived DCs and macrophages, was demonstrated. In conclusion, the Nb display technology is an attractive approach to generate LVs targeted to specific cell types.Gene Therapy advance online publication, 12 January 2012; doi:10.1038/gt.2011.206. |
| | |
Authors:
|
C Goyvaerts; K De Groeve; J Dingemans; S Van Lint; L Robays; C Heirman; J Reiser; X-Y Zhang; K Thielemans; P De Baetselier; G Raes; K Breckpot |
Related Documents
:
|
20162407 - Characterization of a calcitonin gene-related peptide release assay in rat isolated dis... 10719667 - Collectins and pulmonary innate immunity. 15211087 - Host defense functions of pulmonary surfactant. 7507497 - Lipopolysaccharide induces substance p in sympathetic ganglia via ganglionic interleuki... 18252867 - Human langerhans cells selectively activated via toll-like receptor 2 agonists acquire ... 20620937 - Only the strong survive. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-12 |
Journal Detail:
|
Title: Gene therapy Volume: - ISSN: 1476-5462 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9421525 Medline TA: Gene Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A simple detection system for adenovirus receptor expression using a telomerase-specific replication...
Next Document: AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune respo...